Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Sales: 2018-2025

Historic Return on Sales for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Sep 2025 value amounting to -218.56%.

  • Crinetics Pharmaceuticals' Return on Sales was N/A to -218.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -218.56%, marking a year-over-year change of. This contributed to the annual value of -286.26% for FY2024, which is 23413.00% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Return on Sales of -218.56% as of Q3 2025, which was down 43.82% from -151.97% recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Return on Sales ranged from a high of -27.40% in Q1 2022 and a low of -218.56% during Q3 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' Return on Sales averaged around -104.42%, with its median value being -77.88% (2024).
  • Data for Crinetics Pharmaceuticals' Return on Sales shows a maximum YoY plummeted of 13,844bps (in 2025) over the last 5 years.
  • Over the past 4 years, Crinetics Pharmaceuticals' Return on Sales (Quarterly) stood at -34.53% in 2022, then crashed by 699bps to -42.12% in 2023, then tumbled by 6,829bps to -106.45% in 2024, then crashed by 4,552bps to -218.56% in 2025.
  • Its Return on Sales stands at -218.56% for Q3 2025, versus -151.97% for Q2 2025 and -187.75% for Q1 2025.